Germline mutations in BRCA1 and BRCA2 genes occur in up to 18% of patients with high-grade serous ovarian carcinomas (HGSOC), which are responsible for the vast majority of ovarian cancer deaths [1,2]. This evidence concerns the gene BRCA2 and ovarian carcinoma.